company's the bring milestones work we to as build patients. towards near-term foundation commercial join an the for thank today. and you, to accelerating of Zevra stage with time along regulatory solid our our to Thank clinical honor to truly multiple at Nichol, making lead the and It's for and on rare growth to opportunity me therapies you capabilities have all us achieving to this disease critical
over few on updates. my LaDuane and to development call to the of highlights open provide and our transition the After the turn Then, morning I'll provide I'd What and brief a is it briefly I'll this update that, do questions. key Acer. acquisition to for programs financial speak like on corporate a to
I with understood our intensely well into candidates Zevra's of company, aligned one before listening built and been diseases transformation people with focused Since and organization my the joining path the deep diseases, mission from the technology what therapeutic I've Consistent with delivering on joining last is a build platform stakeholders. with impressed focus living with actively to an the is much the with living on the to I've of meeting month, pro-drug rare accelerate own rare on people to on way. its company, very unwavering been on The with future. to team beliefs, commitment promising
the stability while from CEO. service leading company. her on to also retired that the to to as work become management role along the with and kept I'm to that team, Saluri the opportunity him for growth We a the advance Officer I would Zevra journey to our shareholders She like is its returned now to Board take and programs our recently to dedication to like report within our will and Joe the Development Chief President as Christal moving company thank Christal his also during her for Interim to programs. thank to transition. forward leading has clinical execute continue the Board. remained committed rare company's and have our pleased success. there now plan. disease thank clarity I'd and
interactions which in poised asset XX different Letter. Complete Type Niemann-Pick evaluating Let for the efficacy Since currently XXX raised FDA be to their progressive rare or first studied had of NPC, potentially and our need a no the in in more therapy is date, disease development has U.S. across than Arimoclomol urgent and arimoclomol the me neurologic start address with treatment is To acquired working its genetic U.S., been to safety productive feedback disease, been Response in for the fatal we approved steadily over now in C, option. updates. creating treatment a the clinical have the which awaiting are trials, the with approved subjects. XXXX, people an and clinical we've who has drug
deficiencies that confident resubmission. are being are each raised We of addressed the the in
additional Specifically, as provided the inclusion analysis. the use FDA being is an of evidence scale NPC severity as to clinical of primary well support the preferred
from the ongoing in also New data natural early be the from the data access will and comparisons history studies, programs included generated EU. resubmission the multiple real-world and in nonclinical U.S.
the by of the on will as X-month progression In included Phase which extension of II/III FDA, the is a the of submission, year, reduce a to will PDUFA clinical We Class NDA arimoclomol to review the open-label in be may X-year from arimoclomol for the submission, remain demonstrating track classified date the that addition, II the trial the of subject NPC. long-term data placing further by mid-XXXX. be period expected and potential the in end be resubmission
commercial new U.S. the this in of make laying as the accessible launch soon We're as actively to therapy also possible. arimoclomol to groundwork for people the
and visceral, We raising which the making by market to developing includes presentation, are diagnose. symptoms, it of neurological psychiatric heterogeneous the difficult NPC awareness identify and
of the and reduce As early will focus treatment programs, continue approval testing the advancing treatment. on towards launch, guidelines families tools supporting time to we creating and to to and we the diagnosis genetic support progress potential evolution
NPC this to need their Their for instrumental and the been has partner, treatments with living input approved awareness debilitating trusted elevate people condition. we've alongside building committed a voice. in of worked for As
and develop treatment services work We continue to positive a patient experience. to access provide that will together
for of or people sleepiness, currently XX,XXX With need to I'd to is treatment, dysfunction. approximately unmet to for of United a It with hypersomnia IH. being mechanisms your X remains that candidate excessive approved different action estimated the States Now an treatments clinical key needs FDA are sleep with in cognitive unmet turn like KPXXXX, and attention address IH. treatment our as developed there diagnosed inertia daytime idiopathic
trial. interim results data month, that demonstrated the on dose Phase of well is and all reported KPXXXX sleep for levels dose titration program we tolerated II make rare progress. to development regimens. meaningful portion Our disorders continues open-label at These clinical Last the
profile We address results the be by unique suited are the the may well PK unmet believe need. also to encouraged interim and
program As are XXXX. XX report clinical of These first to the we by to line XXXX. will in expected track sites the the and design trial in across half over top on of inform remain progresses, the IH, III results the continuing at data enrollment be initiated is the which Phase end of U.S.
the In clinical programs. of share development II and addition alongside Phase the under support I I'm progress pleased narcolepsy the and to IH made will be narcolepsy Phase the the that on IH to analyzed the both complete, to trial, IND data data is our study being
genetic diagnosis. damage group to received harmful coma. both to UCDs, potentially in This can OLPRUVA, not the complementary that people acquisition assets with into closing, blood, ammonia that a rare Moving and impairment, indicated some accelerate we to commercial company. of have our mission symptomatic Upon resulting Zevra's proposed bring in who difficult neurocognitive transition cause of cases, identify of rare rare disorders even yet fit up confirmatory therapies making natural for a a is Acer. life-changing diseases. brain asymptomatic, treatment can which to in will a with to build it the our acquire UCDs are or people be disease
for metabolic efficient geneticists the in these and arimoclomol while opportunity good but million not our NPC, specialists centers and between Zevra, neurologists the allow with degree is number clinical U.S. customer-facing us build ongoing such are approximately and diagnosed of concentrated roughly by This close reach are is involved of a realize market are attractive the are to genetic majority only United approximately This the majority with disorders, a will $XXX to at people capabilities, the of treated. There it's there's other States specialists team. a as in The within estimated annually. in experts diagnosed X,XXX and both of half an scale strategic NPC, commercial UCDs synergies prescribers excellence. UCD high and of to treatment, pediatric of also fit work overlap as the case of with and proximity which an
November for scheduled on and vote Zevra impact that serious people approve the will programs the which of for highly lives vote the meeting build time to during opportunity Acer's shareholder deal the X, with Acer place. is This complementary gives mark moment tomorrow, decisive will take rare to a a diseases.
Now I'll on update who an and will over LaDuane, provide hand financial the our results outlook. call to
